Head-to-head comparison of once-weekly semaglutide versus SGLT2 inhibitors in T2D found semaglutide superior for HbA1c and weight loss with different safety profiles.
Key findingHead-to-head comparison of once-weekly semaglutide versus SGLT2 inhibitors in T2D found semaglutide
What the researchers found
Head-to-head comparison of once-weekly semaglutide versus SGLT2 inhibitors in T2D found semaglutide superior for HbA1c and weight loss with different safety profiles.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
US insurance data from 2018-2022 comparing semaglutide OW versus SGLT2i. Patients had HbA1c ≥ 7.0% at initiation.
How the study worked
In publication.
Who was studied
US adults with uncontrolled T2D (HbA1c ≥ 7%) initiating semaglutide OW or SGLT2i (2018-2022)
What this study cannot tell us
In publication.
How to read the evidence
Based on study design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide therapeutic knowledge.
Questions still open
- Long-term implications?
- Comparison to evidence?
- Next research?
Common questions
What does this mean?
How reliable?
Read the original research
Once-Weekly Semaglutide Versus Sodium-Glucose Co-transporter 2 Inhibitors: Real-World Impact on Weight, HbA1c, and Healthcare Resource Utilization in Type 2 Diabetes (PAUSE).
Diabetes therapy : research, treatment and education of diabetes and related disorders, 16(5), 1033-1048
Citation
Amamoo, James; Doshi, Riddhi; Noone, Joshua; Xie, Lin; Gamble, Cory; Guevarra, Mico; Divino, Victoria; Chen, Justin; King, Aaron. (2025). Once-Weekly Semaglutide Versus Sodium-Glucose Co-transporter 2 Inhibitors: Real-World Impact on Weight, HbA1c, and Healthcare Resource Utilization in Type 2 Diabetes (PAUSE).. Diabetes therapy : research, treatment and education of diabetes and related disorders, 16(5), 1033-1048. https://doi.org/10.1007/s13300-025-01721-y